Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05409261Phase 2Active Not Recruiting

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Role: collaborator

NCT05409300Phase 2Active Not Recruiting

Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

Role: collaborator

NCT03403114Completed

Vaccine Attitudes and Practices of Hospital Specialists

Role: collaborator

All 3 trials loaded